A 71-year-old male was diagnosed as a case of high-grade urothelial carcinoma of the bladder 2 years ago. He underwent six cycles of intravesical Bacille Calmette-Guerin and was on clinical follow-up. Now, he presented with hematuria and dysuria for the past 2 months. A contrast-enhanced computed tomography (CT) done 10 days earlier showed a residual/recurrent lesion in the bladder. Transurethral resection showed muscle invasive recurrent urothelial carcinoma. ^99m^Tc-methylene diphosphonate bone scintigraphy was performed for the assessment of skeletal metastasis but showed no abnormal skeletal tracer uptake. However, planar images showed extrarenal pooling of tracer in the left perirenal region \[[Figure 1](#F1){ref-type="fig"}\].

![Whole body ^99m^Tc-methylene diphosphonate bone scintigraphy shows diffuse abnormal tracer activity (arrow) in the left perirenal region. There is no evidence of any osteoblastic skeletal lesions](IJNM-33-68-g001){#F1}

Single photon emission computed tomography-CT (SPECT-CT) performed to localize the abnormal tracer activity demonstrated abnormal tracer pooling in the perirenal collection extending over to the left iliac fossa consistent with a urinary leak \[[Figure 2](#F2){ref-type="fig"}\]. On re-evaluation, a history of mild abdominal pain in the left flank was elicited. In addition, SPECT-CT also identified hypodense liver lesions and parenchymal nodules in the visualized lung segments. In the present clinical context, these findings were consistent with metastatic disease. The patient was managed with immediate percutaneous drainage of the urinary collection. ^99m^Tc-ethylene dicysteine (EC) diuretic renography done the following day showed slow pooling of tracer activity in the region of lower pole of the left kidney in the initial dynamic study \[[Figure 3](#F3){ref-type="fig"}\]. The subsequent prevoid, postvoid, and delayed images at 3 h also showed abnormal tracer activity in the perinephric and lower polar region of the left kidney. A whole body (vertex to midthigh) positron emission tomography-CT performed 2 days after the bone scan also showed tracer-avid lesions in the liver and lungs, further characterizing the malignant/metastatic nature of these lesions. The patient is currently undergoing chemotherapy.

![Single photon emission computed tomography-computed tomography of the abdomen shows perirenal collection of tracer activity in orthogonal views (a -axial, b - sagittal, c - coronal) consistent with perirenal leak. In addition, non tracer-avid hepatic (d) and pulmonary lesions (e) are detected on computed tomography](IJNM-33-68-g002){#F2}

![^99m^Tc-ethylene dicysteine renal scintigraphy shows pooling of tracer in the region of the lower pole of the left kidney in dynamic (a), prevoid (b), postvoid (c), and delayed (d) static images](IJNM-33-68-g003){#F3}

Urinary leak although common after abdominal trauma may also result from transmitted backpressure from a ureteral stone, pelvic mass, pregnancy, retroperitoneal fibrosis, or ureteropelvic junction obstruction. Ureteric obstruction by neoplasm is a rare cause of spontaneous urinary leak.\[[@ref1]\] Urinoma resulting from bladder malignancy is rare and usually associated with vesicoureteric junction involvement.\[[@ref2][@ref3]\] Although bone scan is not used for evaluation of urinary leak *per se*, the accumulation of radiotracer outside the urinary system can be detected with SPECT-CT. Although there are reports of urinary leak diagnosed from other tracers,\[[@ref4][@ref5][@ref6][@ref7]\] the diagnosis of unsuspected urinary leak from bone scan is rare.\[[@ref8][@ref9]\] In this patient, hybrid scintigraphic imaging diagnosed an unsuspected urinary leak and also detected nonskeletal distant metastases, thereby aiding in clinical management.
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